Article
An Immunogenic Model of KRAS-Mutant Lung Cancer Enables Evaluation of Targeted Therapy and Immunotherapy Combinations.
Cancer research - 4 Oct 2022
Boumelha Jesse, de Carné Trécesson Sophie, Law Emily K, Romero-Clavijo Pablo, Coelho Matthew A, Ng Kevin W, Mugarza Edurne, Moore Christopher, Rana Sareena, Caswell Deborah R, Murillo Miguel, Hancock David C, Argyris Prokopios P, Brown William L, Durfee Cameron, Larson Lindsay K, Vogel Rachel I, Suárez-Bonnet Alejandro, Priestnall Simon L, East Philip, Ross Sarah J, Kassiotis George, Molina-Arcas Miriam, Swanton Charles, Harris Reuben, Downward Julian
Abstract excerpt
Mutations in oncogenes such as KRAS and EGFR cause a high proportion of lung cancers. Drugs targeting these proteins cause tumor regression but ultimately fail to elicit cures. As a result, there is an intense interest in how to best combine targeted therapies with other treatments, such as immunotherapies. However, preclinical systems for studying the interaction of lung tumors with the host immune system are...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.